IND for iCo

Article

iCo Therapeutics, an Isis Pharmaceuticals licensee, has filed an Investigational New Drug (IND) application with the FDA for iCo-007.

iCo Therapeutics, an Isis Pharmaceuticals licensee, has filed an Investigational New Drug (IND) application with the FDA for iCo-007.

iCo-007, for the treatment of eye diseases such as age-related macular degeneration and diabetic retinopathy, is a second generation drug that inhibits the production of c-Raf kinase, an enzyme associated with the development of new blood vessels in the eye.

Isis will receive a milestone payment from iCo based on the IND filing.

Related Videos
Ms Neeru Vallabh on a virtual call with Ophthalmology Times Europe
A screenshot of Dr Filomena Ribeiro, president of the ESCRS
Ramin Tadayoni, MD, speaks with Sheryl Stevenson
Jennifer I. Lim, MD, FARVO, FASRS, Director of Retina Service, University of Illinois at Chicago
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center
Carl D. Regillo, MD, FACS, FASRS, Chief of Retina Service, Wills Eye Hospital, Philadelphia, PA
© 2024 MJH Life Sciences

All rights reserved.